ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Characterization of acute dengue immune status and serotype surveillance in three regions of Burkina Faso: a hospital-based cross-sectional study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionIn recent years, dengue has become a significant public health concern in Burkina Faso, associated with severe disease and death. Rapid characterization of acute dengue serostatus is useful for identifying patients at risk, informing transmission dynamics, and supporting public health decision-making. This study aimed to characterize dengue immune status in three regions of Burkina Faso to inform pre-vaccination screening, evaluate a commercial combined DENV NS1, IgM, and IgG rapid diagnostic test (RDT) kit, and investigate DENV serotype circulation.
methodsA multicenter study was conducted between 2023 and 2025 in Bobo-Dioulasso, Houndé, Ouagadougou, and Gaoua. Blood samples were collected from patients with suspected dengue. Acute DENV infections and serotypes were identified using real-time RT-PCR, and immune status was characterized by enzyme-linked immunosorbent assay (ELISA) according to WHO criteria. Serum samples were screened using the reference standard (RT-PCR combined with ELISA) to evaluate the performance of a commercial DENV NS1, IgM, and IgG RDT kit in characterizing dengue immune status.
resultsPrimary dengue accounted for 75.9%, 80.4%, and 71.4% in 2023, 2024, and 2025, respectively. The sensitivity of the RDT for determining primary and post-primary dengue during the first 5 days of illness was 93.3% and 94.7%, respectively. DENV-1, DENV-2, and DENV-3 accounted for 47.0%, 5.6%, and 47.4% of cases, respectively. DENV-4 was not detected. The diagnostic specificity of the RDT for both primary and post-primary dengue was 100%.
conclusionsPrimary dengue cases predominated, while severe dengue was associated with post-primary infection. The RDT proved to be a useful point-of-care tool for discriminating dengue immune status. DENV-3 and DENV-1 were the predominant serotypes driving recent transmission dynamics. The findings may help inform future vaccination strategies.
Indexed as
Identifiers
42850544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.